# CAMPASS (NCT04964479)

> A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

No report yet. It can be ordered.

- Drugs tested: benmelstobart plus anlotinib
- Indication: PD-L1-positive advanced non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04964479
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions: Non Small Cell Lung Cancer
- Interventions: TQB2450 injection; Anlotinib Hydrochloride Capsules; Pembrolizumab injection; Placebo
- Enrollment: 375
- Primary outcome: Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)

## Indexed commentary on CAMPASS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=campass-nct04964479

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04964479", "email": "<work email>"}; the inbox owner confirms by the emailed link.